Liraglutide

Main evidence: Human clinical trials. Updated 2026-10-28.

What research and users report, not a recommendation or medical advice. Many of these products are not approved for human use. Ask your doctor. Packs report what sources say, each with its evidence label. A claim labelled community, educator, manufacturer or animal has not been validated in humans.

Summary

This pack summarizes published evidence, dosing context, safety considerations, and Australian legal status for Liraglutide.

What the sources say

In the LEADER cardiovascular-outcomes trial in type 2 diabetes, liraglutide reduced the primary major adverse cardiovascular event outcome compared with placebo (hazard ratio 0.87, 95% CI 0.78–0.97); this is evidence for the studied population and regimen, not every use of liraglutide. (Human clinical trials; Marso et al., "Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes" (LEADER), 2016-07-28)
WebMD patient reviews describe a mix of reported appetite or weight changes and gastrointestinal effects such as nausea; these unverified user accounts cannot establish incidence, causation or expected results, and are not clinical evidence. (Community reports; WebMD, "User Reviews for Saxenda (Liraglutide)", 2026-10-28)
Liraglutide is a GLP-1 analogue; the Australian Saxenda Product Information describes a product-specific use for chronic weight management. (Educator material (not peer reviewed); TGA, Australian Public Assessment Report attachment: Product Information for liraglutide (Saxenda), 2019-04-29)
The TGA reports that evidence was insufficient to establish a causal association between GLP-1 receptor agonists and suicidal or self-harming behaviours, but it aligned product warnings and advises monitoring for new or worsening depression, suicidal thoughts or unusual mood or behaviour changes. (Educator material (not peer reviewed); TGA, "GLP-1 RAs: warnings aligned over potential risk of suicidal thoughts or behaviours", 2025-12-01)
The Australian label identifies gastrointestinal effects and warnings requiring clinical assessment, including pancreatitis and gallbladder-related concerns; the risk information is product-label context and does not predict an individual outcome. (Educator material (not peer reviewed); TGA, Australian Public Assessment Report attachment: Product Information for liraglutide (Saxenda), 2019-04-29)
The June 2026 Poisons Standard lists liraglutide in Schedule 4, the prescription-only schedule. (Educator material (not peer reviewed); Australian Government, Therapeutic Goods (Poisons Standard—June 2026) Instrument 2026, 2026-05-28)

Sources

Dosing, stacking and protocol details are not published here.